VC-backed Gritstone debuts IPO

Emeryville, California-based Gritstone Oncology Inc, a developer of tumor-specific cancer immunotherapies, has raised about $100 million after pricing its IPO of over 6.6 million shares at $15 per share. The stock began trading September 28, 2018 on the NASDAQ under the ticker symbol "GRTS." Goldman Sachs, Cowen and Company LLC and Barclays Capital Inc are the lead underwriters. Gritstone Oncology’s pre-IPO backers included Versant Ventures, The Column Group, Clarus Funds, Frazier Healthcare Partners, RedMile, Casdin Capital, Lilly Asia Ventures, Trinitas Capital, GV, Alexandria Venture Investments and Bay City Capital.

ManagersNorth AmericaUSHealthcareBriefs